SG Americas Securities LLC Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

SG Americas Securities LLC bought a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 24,493 shares of the company’s stock, valued at approximately $388,000. SG Americas Securities LLC owned approximately 0.06% of Keros Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in KROS. KBC Group NV increased its stake in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. acquired a new stake in Keros Therapeutics in the third quarter worth about $89,000. LMR Partners LLP acquired a new stake in Keros Therapeutics in the third quarter worth about $213,000. Finally, Victory Capital Management Inc. acquired a new stake in Keros Therapeutics in the third quarter worth about $216,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS opened at $11.13 on Tuesday. The company’s 50-day moving average price is $26.98 and its two-hundred day moving average price is $44.77. Keros Therapeutics, Inc. has a one year low of $9.77 and a one year high of $73.00. The stock has a market capitalization of $450.84 million, a PE ratio of -2.14 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $0.39 million for the quarter. During the same quarter in the previous year, the business earned ($1.33) earnings per share. Keros Therapeutics’s quarterly revenue was up 4750.0% on a year-over-year basis. On average, analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. TD Cowen cut Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. HC Wainwright reduced their target price on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Guggenheim reiterated a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Oppenheimer dropped their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a report on Thursday, January 16th. Finally, Piper Sandler cut their price objective on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, January 17th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $52.56.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.